M&A

AstraZeneca buys bacterial vaccine biotech Omniose after research tie-up

AstraZeneca acquired Omniose, a preclinical company, on undisclosed terms rather than renewing their bacterial vaccine collaboration. Omniose's platform makes and joins conjugate vaccine parts within engineered bacterial cells. Its candidates have yet to reach human testing.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call